Claude Autonomously Designs Protein Binders, Confirmed in Blinded Wet-Lab Tests

Strip away the headline number and what actually happened inside Claude Science was mostly an exercise in delegation. The pipeline ran on a roughly 16,000-word system prompt, and about two-thirds of it was devoted to scheduling, delegating to sub-agents, verification, and budget discipline rather than any scientific guidance ^[1]. Anthropic did not train a new protein-design model for this - Claude instead orchestrated roughly a dozen existing open-source structure-generation and optimization tools, among them PXDesign, RFdiffusion3, Genie 3, FreeBindCraft, and SolubleMPNN ^[1][2]. Three tools did most of the actual structural work: PXDesign generated 358 of the designs, RFdiffusion3 267, and Genie 3 185 ^[2].

That distinction matters more than it sounds. Every one of those generators was trained on largely the same protein-structure data, and several had already been wet-lab validated by their own creators before Claude ever called them ^[1][2]. So when a design fails, it tends to fail for a shared underlying reason rather than being caught by a different tool's blind spot. The genuinely new capability on display isn't a smarter model of proteins - it's an agent that can navigate a dozen finicky, differently-documented scientific tools end to end with almost no human intervention, deciding which tool to call, when to retry, and when to stop. Independent YouTube breakdowns of the release converged on the same read almost immediately, drawing a sharp line between how many targets Claude touched and how well any single design actually bound - treating the orchestration itself, not a new protein model, as the real story.

Averaged across all 15 targets, Claude's two model configurations landed hit rates from 22.6 percent (Opus 4.8, multi-target mode) up to 35.1 percent (Mythos Preview, single-target mode) ^[3][4], against a 10-15 percent baseline drawn from the Proteinbase database of past de novo design campaigns ^[1]. The single best-ranked design per target bound 49 percent of the time ^[3].

But the average hides a huge spread. Against TREM2, Claude's designs bound in 72 of 90 attempts - an 80 percent hit rate, more than double the 38.3 percent a prior open Adaptyv competition achieved on the same target ^[5]. Against RBX1, Claude bound about 31 percent of designs versus roughly 3.7 percent in an earlier open competition, and its tightest binder measured 3.9 nanomolar affinity against the competition winner's 45 nanomolar ^[3][5]. Against maltose-binding protein, though, Claude went 0 for 90 ^[2][4]. The pattern holds across the coverage: Claude does best on well-studied, well-represented targets, and its failure mode isn't graceful degradation - it's a wall.

To its credit, Anthropic didn't just grade its own homework. Two independent contract labs, Adaptyv Bio and Twist Bioscience, synthesized and tested separate portions of Claude's designs, and neither lab saw the other's data, nor which model, campaign, or ranking corresponded to each sequence during measurement ^[2][5]. Adaptyv's own case study describes converting sequences to DNA, expressing them via cell-free protein synthesis (95 percent of designs expressed successfully), and measuring binding strength with Surface Plasmon Resonance across five concentrations in duplicate ^[5]. Anthropic also released the complete underlying dataset - 129,003 files, 9.9 GB - under a CC BY 4.0 license, with processing code under MIT, posted to Hugging Face and Proteinbase ^[2].

That's a genuinely higher bar than a typical lab press release. It is not, however, peer review. Anthropic itself flagged that the results are self-reported and haven't gone through outside review, and that no matched human-expert control group ran the same 15 targets under the same conditions for direct comparison ^[6]. Reaction on r/singularity captured that tension: alongside enthusiasm - including from readers personally affected by the diseases involved - a recurring thread of skepticism pushed back specifically on the lack of independent replication and raised statistical concerns about how much a 22-35 percent hit-rate range can vary given the sample sizes involved, while other commenters argued the real bottleneck in protein design was never the design step at all but the slower, costlier wet-lab testing that follows it. On X, the shape of the reaction was different: Anthropic's own announcement drew far more engagement than any independent commentary, and the most notable corroboration came from a researcher who appears to have worked on the project directly, backing the headline hit-rate claim from what reads as an insider vantage point rather than disputing it. Both critiques are fair, and neither is fully answered by a blinded internal study, however carefully blinded - only an outside group running the same pipeline on new targets would settle it.

The sharpest pushback on the results came from Martin Shkreli, who argued the binders aren't clinically meaningful: affinities are too low for peptide-based binders, none of the designs work intracellularly, and for a purely extracellular probe a monoclonal antibody already does the job better ^[7]. Adaptyv Bio's own read is more measured but points the same direction - it called Claude at least expert-level at orchestrating protein design tools that are notoriously hard to use ^[1]. That expert-level orchestration claim is itself a narrower one than it might sound: a confirmed binder is only the first of many steps before optimization for stability, selectivity, manufacturability, and safety even begins.

Anthropic's own rollout decisions echo that caution. Even though the pipeline worked inside Claude Science, protein design and other dual-use biology capabilities remain unavailable in Claude Fable 5, Anthropic's most capable general-purpose model, citing dual-use biosecurity risk ^[1][4]. The company describes launching a dedicated access program for scientists as one of its highest priorities, with more detail still to come ^[4]. Independent YouTube coverage of the release picked up on the same tension unprompted, with at least one breakdown flagging the dual-use safety caveat as the story's other half. In other words: the same organization publishing '14 of 15 targets' as a headline number is also the one keeping the tool locked down for almost everyone else - which reads less like marketing caution and more like an honest admission that the gap between 'binder' and 'drug' is still wider than the top-line stat suggests.